Pfizer this week unveiled a $11.6 billion deal to acquire Biohaven, the biotech known for its migraine drug Nurtec ODT. The oral CGRP inhibitor can be used to both treat and prevent migraines. For the treatment of migraines, Nurtec ODT holds covered or better status for 88% of all insured lives under the pharmacy benefit. Other oral therapies in the growing migraine space include two AbbVie drugs, Ubrelvy (86% covered or better status) and Qulipta (56%).
SOURCE: MMIT Analytics, as of 5/11/22